-
公开(公告)号：US10730897B2
公开(公告)日：2020-08-04
申请号：US16472579
申请日：2017-12-21
申请人： GE HEALTHCARE AS
IPC分类号： C07F13/00
摘要： The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.
-
公开(公告)号：US10576169B2
公开(公告)日：2020-03-03
申请号：US15531431
申请日：2015-11-27
申请人： GE HEALTHCARE AS
IPC分类号： A61K49/10 , C07D257/00 , A61K9/00 , A61K31/28
摘要： The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.
-
公开(公告)号：US20170258944A1
公开(公告)日：2017-09-14
申请号：US15531430
申请日：2015-11-27
申请人： GE HEALTHCARE AS
IPC分类号： A61K49/10
CPC分类号： A61K49/108 , A61K49/10 , A61K49/18
摘要： The present invention relates to a method of preparation of formulations of gadolinium metal complexes of the macrocyclic chelator DOTA, which further comprise a small excess of free DOTA. The method uses controlled conditions such that excess gadolinium is present as a precipitate of gadolinium oxide, with filtration to remove the excess, prior to the addition of a defined excess of DOTA chelator. Also provided is a method of preparation of MRI contrast agents based on Gd-DOTA.
-
公开(公告)号：US20230025866A1
公开(公告)日：2023-01-26
申请号：US17787545
申请日：2020-12-18
申请人： GE Healthcare AS
IPC分类号： A61K49/10
摘要： The present invention provides a novel method for removal of gadolinium ions from a solution comprising gadolinium complexed with DOTA. The method of the invention is relatively straightforward and cost-efficient compared with known methods.
-
公开(公告)号：US12070511B2
公开(公告)日：2024-08-27
申请号：US17851454
申请日：2022-06-28
申请人： GE HEALTHCARE AS
IPC分类号： A61K49/10 , A61K9/00 , A61K31/28 , C07D257/00
CPC分类号： A61K49/108 , A61K9/0019 , A61K31/28 , A61K49/106 , C07D257/00
摘要： The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.
-
公开(公告)号：US11884686B2
公开(公告)日：2024-01-30
申请号：US16311564
申请日：2017-06-20
申请人： GE HEALTHCARE AS
IPC分类号： C07F13/00 , C07D471/08
CPC分类号： C07F13/005 , C07D471/08
摘要： The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.
-
公开(公告)号：US10314927B2
公开(公告)日：2019-06-11
申请号：US15531430
申请日：2015-11-27
申请人： GE HEALTHCARE AS
摘要： The present invention relates to a method of preparation of formulations of gadolinium metal complexes of the macrocyclic chelator DOTA, which further comprise a small excess of free DOTA. The method uses controlled conditions such that excess gadolinium is present as a precipitate of gadolinium oxide, with filtration to remove the excess, prior to the addition of a defined excess of DOTA chelator. Also provided is a method of preparation of MRI contrast agents based on Gd-DOTA.
-
公开(公告)号：US20180303960A1
公开(公告)日：2018-10-25
申请号：US15768831
申请日：2016-11-30
申请人： GE Healthcare AS
发明人： Andreas Richard Meijer , Mikkel Jacob Thaning , Paritosh Jayant Dhawale , Salvatore Desena , Paul Alexander Jones , Deirdre Cassidy , Concetta Valeria Gringeri
IPC分类号： A61K49/10
CPC分类号： A61K49/105 , A61K49/101 , A61K49/108 , A61K2123/00
摘要： The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.
-
公开(公告)号：US11186553B2
公开(公告)日：2021-11-30
申请号：US15531429
申请日：2015-11-27
申请人： GE HEALTHCARE AS
摘要： The present invention relates to a method of preparation of formulations of lanthanide metal complexes of macrocyclic chelators which further comprise a small excess of free chelator. The method uses a solid phase-bound scavenger chelator to remove excess lanthanide metal ions, prior to the addition of a defined excess chelator. Also provided is a method of preparation of MRI contrast agents, together with solid-phase bound chelator meglumine salts useful in the methods.
-
公开(公告)号：US10941124B2
公开(公告)日：2021-03-09
申请号：US16062205
申请日：2016-12-19
申请人： GE Healthcare AS
发明人： Andreas Richard Meijer , Arne Wang Aabye , Khalid Hussain , Sondre Nilsen , Mikkel Jacob Thaning , Jarle Andre Haugan , Ingvil Gausemel , Nikolai Enes , Silalahi Sumihar
IPC分类号： C07D257/02 , B01D9/00
摘要： The present invention provides methods for the preparation of compounds useful in in vivo therapeutic and diagnostic applications. In particular, the present invention provides a method for the synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and also methods for the preparation of metal chelates of DOTA.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.017 秒)
